-
31.发明公开METHODS AND COMPOSITIONS FOR TREATING ANDROGEN-DEPENDENT DISEASES USING OPTICALLY PURE R-(-)-CASODEX 失效方法和组合物用于治疗雄激素依赖性疾病VERWENDDUNG光学纯的R - （ - ）CASODEX
公开(公告)号：EP0748220A1
公开(公告)日：1996-12-18
申请号：EP95908626.0
申请日：1995-01-20
Applicant: SEPRACOR, INC.
Inventor： GRAY, Nancy, M.
CPC classification number: A61K31/277 , A61K31/275 , Y10S514/859
Abstract: Methods and compositions are disclosed utilizing optically pure R-(-)-casodex for the treatment of androgen-dependent prostate cancer, while substantially reducing the concomitant liability of adverse effects associated with the central antiandrogen activity of the racemic mixture of casodex. R-(-)-casodex is a peripherally selective antiandrogen and is therefore useful in the treatment of other conditions supported by androgen or caused by elevated androgen levels. Such conditions include benign prostatic hypertrophy or hyperplasia, acne and hirsutism.
-
32.发明公开TERFENADINE METABOLITES AND THEIR OPTICALLY PURE ISOMERS FOR TREATING ALLERGIC DISORDERS 失效Terfanadin代谢产物和它们的光学纯异构体来治疗疾病vonallegischen
公开(公告)号：EP0701443A1
公开(公告)日：1996-03-20
申请号：EP93918584.0
申请日：1993-08-03
Applicant: SEPRACOR, INC. , GEORGETOWN UNIVERSITY
Inventor： YOUNG, James, W. , GRAY, Nancy, M. , WOOSLEY, Raymond, L. , CHEN, Yiwang
CPC classification number: A61K45/06 , A61K31/445 , A61K2300/00
Abstract: A pharmaceutical composition comprising a compound of formula (I): wherein Z is COOH, COOCH3 or CH2OH, or a pharmaceutically acceptable salt thereof, for use in an anti-histaminic treatment which does not induce any significant cardiac arrhythmia, comprising administering a therapeutically effective amount of a compound of formula (I) to a human patient.
-
33.发明公开METHODS AND COMPOSITIONS OF (+) DOXAZOSIN FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA AND ATHEROSCLEROSIS 失效方法和组合物（+） - 多沙唑嗪前列腺癌和动脉粥样硬化BENIGNERE的治疗。
公开(公告)号：EP0667775A1
公开(公告)日：1995-08-23
申请号：EP94900492.0
申请日：1993-11-02
Applicant: SEPRACOR, INC.
Inventor： GRAY, Nancy, M.
CPC classification number: A61K31/505
Abstract: Methods and compositions are disclosed utilizing the optically pure (+) isomer of doxazosin. This compound is a potent drug for the treatment of benign prostatic hyperplasia while avoiding the concomitant liability of hypotensive effects associated with the racemic mixture of doxazosin. The optically pure (+) isomer of doxazosin is also useful for the treatment and prevention of atherosclerosis and other conditions related to elevated serum LDL and cholesterol levels, such as coronary artery disease, without the concomitant liability of adverse effects associated with the racemic mixture of doxazosin.
-
34.发明公开ANTINEOPLASTIC METHODS AND COMPOSITIONS EMPLOYING OPTICALLY PURE (-)-FOTEMUSTINE 失效（ - ） - FOTEMUSTINE的抗移植方法和组合物
公开(公告)号：EP0866712A1
公开(公告)日：1998-09-30
申请号：EP96941430.0
申请日：1996-11-19
Applicant: SEPRACOR, INC.
Inventor： GRAY, Nancy, M.
CPC classification number: A61K31/662
Abstract: Methods and compositions are disclosed utilizing optically pure (-)-fotemustine for the treatment of various malignancies, while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of fotemustine.
Abstract translation: 公开了使用光学纯的（ - ） - 福莫司汀用于治疗各种恶性肿瘤的方法和组合物，同时显着降低与福莫司汀的外消旋混合物相关的副作用的伴随可能性。
-
Patent Agency Ranking35.发明授权TERFENADINE METABOLITES AND THEIR OPTICALLY PURE ISOMERS FOR TREATING ALLERGIC DISORDERS 失效Terfanadin代谢产物和它们的光学纯异构体来治疗过敏性疾病
公开(公告)号：EP0701443B1
公开(公告)日：1998-01-21
申请号：EP93918584.9
申请日：1993-08-03
Applicant: SEPRACOR, INC. , GEORGETOWN UNIVERSITY
Inventor： YOUNG, James, W. , GRAY, Nancy, M. , WOOSLEY, Raymond, L. , CHEN, Yiwang
IPC: A61K31/445
CPC classification number: A61K45/06 , A61K31/445 , A61K2300/00
Abstract: A pharmaceutical composition comprising a compound of formula (I): wherein Z is COOH, COOCH3 or CH2OH, or a pharmaceutically acceptable salt thereof, for use in an anti-histaminic treatment which does not induce any significant cardiac arrhythmia, comprising administering a therapeutically effective amount of a compound of formula (I) to a human patient.
-
36.发明公开METHODS AND COMPOSITIONS FOR TREATING GASTRIC DISORDERS USING OPTICALLY PURE (+) PANTOPRAZOLE 失效使用光学纯（+）戊内酯治疗胃病的方法和组合物
公开(公告)号：EP0700292A1
公开(公告)日：1996-03-13
申请号：EP94914911.0
申请日：1994-04-25
Applicant: SEPRACOR, INC.
Inventor： GRAY, Nancy, M.
CPC classification number: A61K31/44
Abstract: Methods and compositions are disclosed utilizing optically pure (+) pantoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of pantoprazole. The optically pure (+) isomer is also useful for the treatment of gastroesophageal reflux. (+) Pantoprazole is an inhibitor of H+ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.
Abstract translation: 公开了使用光学纯（+）泮托拉唑治疗人类溃疡的方法和组合物，同时显着降低与泮托拉唑外消旋混合物相关的副作用的伴随可能性。 光学纯的（+）异构体也可用于治疗胃食管反流。 （+）泮托拉唑是H +释放的抑制剂，因此可用于治疗与胃高分泌有关的其他病症，如Zollinger-Ellison综合征。
-
公开(公告)号：EP0697868A1
公开(公告)日：1996-02-28
申请号：EP94916066.0
申请日：1994-05-10
Applicant: SEPRACOR, INC.
Inventor： GRAY, Nancy, M.
CPC classification number: A61K31/38
Abstract: Methods and compositions are disclosed utilizing optically pure (+)-zileuton for the treatment of asthma, rheumatoid arthritis and ulcerative colitis in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of zileuton. (+)-Zileuton is an inhibitor of 5-lipoxygenase and is therefore useful in the treatment of other conditions related to elevated leukotriene levels. (+)-Zileuton is also an antioxidant and is therefore useful in treating or preventing atherosclerosis.
-
38.发明公开METHODS AND COMPOSITIONS OF (+) DOXAZOSIN FOR THE TREATMENT OF HYPERTENSION 失效方法和组合物（+） - 多沙唑嗪治疗高血压病。
公开(公告)号：EP0667776A1
公开(公告)日：1995-08-23
申请号：EP94900548.0
申请日：1993-11-02
Applicant: SEPRACOR, INC.
Inventor： GRAY, Nancy, M.
CPC classification number: A61K31/505
Abstract: Methods and compositions are disclosed utilizing the optically pure (+) isomer of doxazosin. This compound is a potent drug for the treatment of hypertension while avoiding the concomitant liability of adverse effects associated with the racemic mixture of doxazosin.
-
39.发明公开METHODS OF USING (-) CISAPRIDE FOR THE TREATMENT OF GASTRO-ESOPHAGEAL REFLUX DISEASE AND OTHER DISORDERS 失效法使用（ - ） - 西沙必利胃SPEISEROEHRENRUECHSTORNUNG等疾病的治疗。
公开(公告)号：EP0649307A1
公开(公告)日：1995-04-26
申请号：EP93916996.0
申请日：1993-07-06
Applicant: SEPRACOR, INC.
Inventor： GRAY, Nancy, M. , YOUNG, James, W.
CPC classification number: A61K31/445 , A61K31/4468
Abstract: Methods are disclosed utilizing the optically pure (-) isomer of cisapride. This compound is a potent drug for the treatment of gastro-esophageal reflux disease while avoiding the concomitant liability of adverse effects associated with the racemic mixture of cisapride. This compound is also useful in treating or preventing emesis while avoiding the adverse effects associated with racemic cisapride. The optically pure (-) isomer of cisapride is also useful for the treatment of dyspepsia and such other conditions as may be related to the activity of (-) cisapride as a prokinetic agent such as gastroparesis, constipation, post-operative ileus, and intestinal pseudo-obstruction without the concomitant liability of adverse effects associated with the racemic mixture of cisapride. The (-) isomer of cisapride has been found to exhibit higher bioavailability over the racemic cisapride.
-
-
-
-
-
-
-
-
Search Results
39
records
(took 0.021 seconds)
